December 5th, 2023
United Immunity’s UI-102 has been selected by AMED as “Strengthening Program for Pharmaceutical Startup Ecosystem”.
United Immunity’s UI-102 has been selected by AMED as “Strengthening Program for Pharmaceutical Startup Ecosystem”. This program would give us step by step financial support (total double digit million dollars expected) from preclinical to human proof of concept studies.
UI-102 is a potential best in class systemic immune modulator leveraging our Myeloid Targeting PlatformTM to treat patients suffering from cold tumors. We are thankful for all of our supporters.